Incyte Genomics Inc (INCY)
Health Care ยท Services-Commercial Physical & Biological Research
Incyte Genomics Inc (INCY) is listed on Nasdaq, where its shares have traded since November 3, 1993. SentiSense covers Incyte Genomics Inc in the Health Care sector, and its Standard Industrial Classification is Services-Commercial Physical & Biological Research. Bill Meury is its chief executive officer. The company reports 2,844 employees, and its corporate website is www.incyte.com.
About Incyte Genomics Inc
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 840 institutions reported holding INCY, with 201.2 million shares worth $22.8 billion in aggregate. The largest reported holders were Baker Bros. Advisors, Vanguard and BlackRock. Of the 5 largest reported holders, 3 added shares and 2 reduced their positions during the quarter.
More on INCY
- INCY sentiment: whether news and social coverage of Incyte Genomics Inc leans bullish or bearish, and the stories driving it.
- INCY ownership: all 840 reporting institutions, plus insider and congressional trades.
- INCY financials: revenue, net income, operating margin and free cash flow by quarter and year.
SentiSense also tracks daily options readings for Incyte Genomics Inc: IV rank, put/call percentile, 25-delta skew and open-interest walls.
Frequently asked questions
What does Incyte Genomics Inc do?
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis.
What sector is INCY in?
SentiSense classifies Incyte Genomics Inc in the Health Care sector, and its Standard Industrial Classification is Services-Commercial Physical & Biological Research.
Where does INCY stock trade?
Incyte Genomics Inc (INCY) is listed on Nasdaq, where its shares have traded since November 3, 1993.
Who is the CEO of Incyte Genomics Inc?
Bill Meury is the chief executive officer of Incyte Genomics Inc.